<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57128">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049333</url>
  </required_header>
  <id_info>
    <org_study_id>ECPLateau10.1</org_study_id>
    <nct_id>NCT02049333</nct_id>
  </id_info>
  <brief_title>Cataract Surgery vs Cataract Surgery With ECPL for Treatment of Plateau Iris Configuration or Syndrome</brief_title>
  <official_title>Phacoemulsification Versus Phacoemulsification With Endoscopic Cycloplasty (ECPL) for Treatment of Plateau Iris Configuration or Syndrome: A Prospective Randomized Clinical and Surgical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Credit Valley EyeCare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Credit Valley EyeCare</source>
  <oversight_info>
    <authority>Canada: Canadian Food &amp; Drug Act &amp; Regulations</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and compare the mechanical angle opening in patients
      with angle closure due to a plateau iris configuration (elevated iris) using
      phacoemulsification combined with endoscopic cycloplasty versus treatment with
      phacoemulsification alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Anterior Chamber Angle Depth (nasal angle)</measure>
    <time_frame>Twelve months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anterior chamber angle depth (nasal angle) measured using the Shaffer grading system and via anterior segment imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of glaucoma medications</measure>
    <time_frame>Twelve months post-op</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of glaucoma medications will be recorded and compared to pre-operative number of glaucoma medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>Twelve months post-op</time_frame>
    <safety_issue>No</safety_issue>
    <description>IOP will be recorded and compared to pre-operative IOP.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intra- and post-operative complications</measure>
    <time_frame>Up to one year after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analyzing any unexpected complications from the surgery such as prolonged hypotony, intraocular pressure spike, prolonged corneal inflammation etc. This will be done during the clinic visit and analyzed under slit lamp examination.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Phacoemulsification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract extraction alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phacoemulsification with Endoscopic Cycloplasty (ECPL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract extraction combined with endoscopic cycloplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacoemulsification</intervention_name>
    <arm_group_label>Phacoemulsification</arm_group_label>
    <arm_group_label>Phacoemulsification with Endoscopic Cycloplasty (ECPL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Cycloplasty (ECPL)</intervention_name>
    <arm_group_label>Phacoemulsification with Endoscopic Cycloplasty (ECPL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has to be â‰¥ 18 years of age of either gender

          -  Nuclear sclerotic cataract graded by LOCS III to be &lt; 5

          -  Diagnosis of Plateau Iris Configuration or Syndrome

          -  No contraindication for cataract or ECPL operation

          -  Written informed consent on IRB approved Informed Consent Form

        Exclusion Criteria:

          -  Hard cataracts, LOCS III 5 and 6

          -  Ciliary body cysts

          -  Clinically significant sequelae from trauma in which angle anatomy/physiology may
             have been compromised (e.g., chemical burns, significant angle recession, blunt
             trauma, etc.)

          -  Congenital anomaly of the irido-trabecular angle

          -  Previous intraocular surgery

          -  Previous laser gonioplasty to either eye

          -  Placement of the intraocular lens in any place other than the capsular bag

          -  Pupilloplasty

          -  Rubeosis

          -  Peripheral anterior synechiae (PAS)  nasal angle and/or &gt;180 degrees of PAS

          -  Neovascular glaucoma; or glaucoma associated with vascular ischemic disorders

          -  Active corneal inflammation or edema (e.g., keratitis, keratoconjunctivitis,
             keratouveitis)

          -  Corneal opacities or disorders that would inhibit visualization of the nasal angle

          -  Chronic ocular inflammatory disease or presence of active ocular inflammation with
             risk for synechial/proliferative changes

          -  Inability to attend regular follow-up assessment or to give informed written consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ike K Ahmed, MD FRCSC</last_name>
    <role>Study Director</role>
    <affiliation>University of Toronto, Toronto, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osler EyeCare</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6V 1B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley EyeCare</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5L 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>January 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Credit Valley EyeCare</investigator_affiliation>
    <investigator_full_name>Iqbal Ike Ahmed</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
